Our research platform empowers researchers, nonprofits, life sciences organizations, payers, and academic labs to accelerate mental health research, generate evidence, and unlock insights.
With our partner Fluence, we have launched a prospective observational study on psychedelic harm reduction and integration in naturalistic care settings. Please see the study website for more information.
In collaboration with preeminent experts at several top academic medical centers, we are assessing long-term patient outcomes throughout naturalistic repeated intravenous ketamine therapy in a very large sample of patients in the community.
In collaboration with the Ketamine Taskforce for Access to Safe Care and Insurance Coverage, we are conducting a prospective study on how ketamine affects activities of daily living and other functional outcomes in CRPS patients.
We are conducting a study on an innovative intramuscular racemic ketamine protocol to elucidate its efficacy and safety for the treatment of TRD, particularly around the relationship between dosage and time to relapse.